Pinnacle Bancorp’s Krystal Biotech KRYS Stock Holding History

Pinnacle Bancorp’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-121	Closed	-$9.69K	–	789
2023 Q1	$9.69K	Buy	+121	New	+$9.51K	﹤0.01%	627

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pinnacle Bancorp's KRYS Position: Q2 2023 in Review

Pinnacle Bancorp sold out of Krystal Biotech (KRYS) in Q2 2023, closing a stake of 121 shares — an estimated $9.69K sold.

Pinnacle Bancorp first reported a position in KRYS in Q1 2023 and held it in 1 quarter. The position peaked at $9.69K in Q1 2023. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

Pinnacle Bancorp reported no remaining Krystal Biotech position as of Q2 2023 after selling out during the quarter.
Pinnacle Bancorp sold 121 Krystal Biotech shares in Q2 2023, an estimated $9.69K.
Pinnacle Bancorp first reported a position in Krystal Biotech in Q1 2023 and held it in 1 quarter.
Pinnacle Bancorp's Krystal Biotech position peaked at $9.69K in Q1 2023.
183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on Pinnacle Bancorp's 13F filing for Q2 2023, filed 14 Jul 2023.